Literature DB >> 17289688

New treatments for neovascular acute macular degeneration.

Usha Chakravarthy, Jennifer I Lim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17289688      PMCID： PMC1796712          DOI： 10.1136/bmj.39100.460671.BE

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

Review 1.  VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection.

Authors:  Erik Storkebaum; Diether Lambrechts; Peter Carmeliet
Journal:  Bioessays       Date:  2004-09       Impact factor: 4.345

2.  Utility values and age-related macular degeneration.

Authors:  G C Brown; S Sharma; M M Brown; J Kistler
Journal:  Arch Ophthalmol       Date:  2000-01

Review 3.  Ranibizumab: Phase III clinical trial results.

Authors:  Philip J Rosenfeld; Ryan M Rich; Geeta A Lalwani
Journal:  Ophthalmol Clin North Am       Date:  2006-09

4.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 7.  How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?

Authors:  C G Owen; A E Fletcher; M Donoghue; A R Rudnicka
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

8.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Authors:  Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2002-03

9.  Pegaptanib for neovascular age-related macular degeneration.

Authors:  Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

Review 10.  Age-related macular degeneration.

Authors:  N M Bressler; S B Bressler; S L Fine
Journal:  Surv Ophthalmol       Date:  1988 May-Jun       Impact factor: 6.048
View more
  4 in total

1.  The cheaper drug, bevacizumab, should be referred to NICE.

Authors:  James P Raftery; Andrew Lotery
Journal:  BMJ       Date:  2007-02-24

2.  NICE appraisals should be everybody's business.

Authors:  Jane Wells; Claire Cheong-Leen
Journal:  BMJ       Date:  2007-05-05

Review 3.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.

Authors:  Usha Chakravarthy; Tien Y Wong; Astrid Fletcher; Elisabeth Piault; Christopher Evans; Gergana Zlateva; Ronald Buggage; Andreas Pleil; Paul Mitchell
Journal:  BMC Ophthalmol       Date:  2010-12-13       Impact factor: 2.209

4.  Career choices for ophthalmology made by newly qualified doctors in the United Kingdom, 1974-2005.

Authors:  Trevor W Lambert; Michael J Goldacre; Anthony J Bron
Journal:  BMC Ophthalmol       Date:  2008-03-04       Impact factor: 2.209
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.